TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia
Brief Summary: To evaluate the long-term safety and efficacy of eszopiclone administered for 12 weeks in elderly subjects with primary chronic insomnia.Administration of eszopiclone 2 mg daily at bedtime for 12 weeks in elderly subjects with a diagnosis of primary chronic insomnia will be safe and well tolerated, improve subjective sleep measures, improve measures of Quality of Life and next day insomnia symptoms, and have no significant withdrawal central nervous system adverse events or rebound insomnia.


Options:
A: Arm Label: 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs); Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone, Drug: Placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Eszopiclone, Placebo
C: Arm Label: Eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Eszopiclone | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): Eszopiclone, Placebo
D: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction | Arm Label: PCT Sleeping Pills; Type: ACTIVE_COMPARATOR; Interventions: Drug: eszopiclone | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction; Assigned to Arm(s): MBSR | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): PCT Sleeping Pills

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients With Severe Sepsis and Multiple Organ Dysfunction
Brief Summary: In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration \[24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours\] or will receive the normal, approved dose or higher doses than the approved dose for a longer administration time. After the drug administration is complete, the protein C levels from the patients receiving the normal, approved dose will be compared to protein C levels from patients receiving the normal, approved dose or higher dose for a longer duration to determine if the protein C levels improve faster if given higher dose and/or longer administration time.

Note: The protocol was amended to remove the option of shorter infusion durations.


Options:
A: Arm Label: Drotrecogin alfa (activated); Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
C: Arm Label: Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:moderate protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: Alternative therapy:severe protein C deficiency; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): Alternative therapy:moderate protein C deficiency, Alternative therapy:severe protein C deficiency, Standard therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Drotrecogin alfa (activated) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drotrecogin alfa (activated); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial
Brief Summary: The objective of the project is to find out whether cleansing the vagina before a cesarean delivery decreases the risk of complications and infections after having the baby. If this is the case, cleansing the vagina before cesarean delivery can help improve outcomes for many women and make their early postpartum recovery much more pleasant, giving a healthier start for the family.


Options:
A: Arm Label: Clorhexidine; Type: EXPERIMENTAL; Interventions: Drug: Clorhexidine | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Intervention Type: DRUG; Name: Clorhexidine; Assigned to Arm(s): Clorhexidine | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): Saline solution
B: Arm Label: Combination iodine and chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination iodine and chlorhexidine | Arm Label: Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine | Arm Label: Iodine povidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iodine povidone | Intervention Type: DRUG; Name: Iodine povidone; Assigned to Arm(s): Iodine povidone | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): Chlorhexidine | Intervention Type: DRUG; Name: Combination iodine and chlorhexidine; Assigned to Arm(s): Combination iodine and chlorhexidine
C: Arm Label: Vag prep; Type: EXPERIMENTAL; Interventions: Procedure: Vaginal cleansing before cesarean delivery | Intervention Type: PROCEDURE; Name: Vaginal cleansing before cesarean delivery; Assigned to Arm(s): Vag prep
D: Arm Label: povidone iodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 10% povidone iodine | Arm Label: no vaginal cleansing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 10% povidone iodine; Assigned to Arm(s): povidone iodine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants and Children.
Brief Summary: This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.


Options:
A: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
B: Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): N/A
C: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
D: Arm Label: co-formulated Amodiaquine-Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine-artesunate (AQAS) fixed-dose | Arm Label: artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination (AL) dispersable | Intervention Type: DRUG; Name: amodiaquine-artesunate (AQAS) fixed-dose; Assigned to Arm(s): co-formulated Amodiaquine-Artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination (AL) dispersable; Assigned to Arm(s): artemether-lumefantrine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This open-label, randomized study will compare the efficacy, safety, and acceptability of mifepristone 200 mg followed in 24-36 hours either by buccal (i.e., in the cheeks) or oral misoprostol 800 mcg for termination of pregnancy in women up to 63 days L.M.P.


Options:
A: Arm Label: mifepristone+misoprostol; Type: EXPERIMENTAL; Interventions: Drug: mifepristone, Drug: misoprostol | Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol, Drug: placebo | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): mifepristone+misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): mifepristone+misoprostol, misoprostol | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): misoprostol
B: Arm Label: Misoprostol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Misoprostol and Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone, Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Misoprostol and Mifepristone | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, Misoprostol and Mifepristone
C: Intervention Type: DRUG; Name: 800 mcg misoprostol via oral or buccal administration; Assigned to Arm(s): N/A
D: Arm Label: Duo test; Type: OTHER; Interventions: Other: Self assessment | Arm Label: Routine follow up; Type: OTHER; Interventions: Other: Routine assessment | Intervention Type: OTHER; Name: Self assessment; Assigned to Arm(s): Duo test | Intervention Type: OTHER; Name: Routine assessment; Assigned to Arm(s): Routine follow up

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind Placebo-Controlled Crossover Study to Investigate the Effects of an Inhaled Corticosteroid on Cardiopulmonary Exercise Parameters in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: F 4.5 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 4.5mg | Arm Label: F 9.0 bid; Type: EXPERIMENTAL; Interventions: Drug: Formoterol Turbuhaler® 9 mg | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Turbuhaler® placebo | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 4.5mg; Assigned to Arm(s): F 4.5 bid | Intervention Type: DRUG; Name: Formoterol Turbuhaler® 9 mg; Assigned to Arm(s): F 9.0 bid | Intervention Type: DRUG; Name: Turbuhaler® placebo; Assigned to Arm(s): PBO
B: Arm Label: 1; Type: OTHER; Interventions: Drug: Fluticasone | Arm Label: 2; Type: OTHER; Interventions: Drug: Fluticasone, Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: tiotropium (Spiriva); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Budesonide/formoterol (Symbicort Turbuhaler) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol (Oxis Turbuhaler) | Intervention Type: DRUG; Name: Budesonide/formoterol (Symbicort Turbuhaler); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Formoterol (Oxis Turbuhaler); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind Placebo-Controlled Crossover Study to Investigate the Effects of an Inhaled Corticosteroid on Cardiopulmonary Exercise Parameters in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: To test the effect of the research study drug, inhaled fluticasone on lung function in exercising patients with Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Intervention Type: DRUG; Name: Advair; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Flovent; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: fluticasone 500 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone 500 mcg + salmeterol 50 mcg; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: OTHER; Interventions: Drug: Fluticasone | Arm Label: 2; Type: OTHER; Interventions: Drug: Fluticasone, Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD
Brief Summary: The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol, Drug: Fluticasone Propionate/Salmeterol Combination Product | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): Arm 1
B: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
C: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A
D: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD
Brief Summary: The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.


Options:
A: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A
B: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
C: Intervention Type: DRUG; Name: tiotropium (Spiriva); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Multicentre, Phase II Study of Oral Lapatinib in Combination With Concurrent Radiotherapy and Cisplatin Versus Radiotherapy and Cisplatin Alone, in Subjects With Stage III, IVA, B Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Brief Summary: This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo. The study is designed to evaluate and compare the two treatment groups with respect to complete response rate at 6 months following chemoradiation completion.


Options:
A: Arm Label: Afatinib (BIBW 2992); Type: EXPERIMENTAL; Interventions: Drug: Afatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Afatinib; Assigned to Arm(s): Afatinib (BIBW 2992)
B: Arm Label: Panitumumab Plus Chemoradiation; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy, Drug: Panitumumab | Arm Label: Chemoradiotherapy Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: RADIATION; Name: Standard Fractionation Radiotherapy; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus Chemoradiation
C: Arm Label: CETUXIMAB AND DASATINIB; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: Dasatinib | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): CETUXIMAB AND DASATINIB | Intervention Type: DRUG; Name: Dasatinib; Assigned to Arm(s): CETUXIMAB AND DASATINIB
D: Arm Label: Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib oral tablets, Drug: radiotherapy, Drug: cisplatin chemotherapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lapatinib oral tablets, Drug: radiotherapy, Drug: cisplatin chemotherapy | Intervention Type: DRUG; Name: Lapatinib oral tablets; Assigned to Arm(s): Lapatinib, Placebo | Intervention Type: DRUG; Name: radiotherapy; Assigned to Arm(s): Lapatinib, Placebo | Intervention Type: DRUG; Name: cisplatin chemotherapy; Assigned to Arm(s): Lapatinib, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Swiss Interventional Study on Silent Ischemia (SWISSI 2)
Brief Summary: Silent ischemia has been shown to negatively affect prognosis in patients after myocardial infarction. However, long-term outcome data in totally asymptomatic patients is missing and it is unknown whether angioplasty in addition to secondary preventive measures is superior to antiischemic drug therapy in these patients. Therefore, the SWISSI 2 study was started 15 years ago with the aim of comparing the effects of angioplasty with medical therapy on long-term outcome in patients with recent myocardial infarction and silent ischemia.


Options:
A: Arm Label: Personalized Risk Information; Type: ACTIVE_COMPARATOR; Interventions: Other: Personalized Heart Attack and Stroke Risk | Arm Label: Standard Education; Type: OTHER; Interventions: Other: Standard Education | Intervention Type: OTHER; Name: Personalized Heart Attack and Stroke Risk; Assigned to Arm(s): Personalized Risk Information | Intervention Type: OTHER; Name: Standard Education; Assigned to Arm(s): Standard Education
B: Intervention Type: PROCEDURE; Name: Percutaneous coronary angioplasty/intervention (PCI); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ischemic drug therapy; Assigned to Arm(s): N/A
C: Arm Label: Usual clinical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DTS intervention; Type: EXPERIMENTAL; Interventions: Other: Direct to Smoker Outreach Program | Intervention Type: OTHER; Name: Direct to Smoker Outreach Program; Assigned to Arm(s): DTS intervention
D: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Colon Cancer
Brief Summary: COLOR trial is a randomized, international, multi center study comparing the outcomes of laparoscopic and conventional resection of colon carcinoma with curative intent. Clinical and operative data will be collected centrally in the coordinating centre in Rotterdam, The Netherlands. Quality of life and costs will be assessed on a national basis.


Options:
A: Arm Label: open rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: open rectal resection | Arm Label: laparoscopic rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic rectal resection | Intervention Type: PROCEDURE; Name: open rectal resection; Assigned to Arm(s): open rectal resection | Intervention Type: PROCEDURE; Name: laparoscopic rectal resection; Assigned to Arm(s): laparoscopic rectal resection
B: Arm Label: OPEN SURGERY; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RECTAL CANCER RESECTION | Arm Label: LAPAROSCOPIC SURGERY; Type: EXPERIMENTAL; Interventions: Procedure: RECTAL CANCER RESECTION | Intervention Type: PROCEDURE; Name: RECTAL CANCER RESECTION; Assigned to Arm(s): LAPAROSCOPIC SURGERY, OPEN SURGERY
C: Intervention Type: PROCEDURE; Name: Laparoscopic surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Conventional surgery; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: OTHER; Interventions: Procedure: surgery | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): 1

Answer: C